Advertisement
Advertisement
Trending on Urology Times
1
Matthew Galsky, MD, on how EV/pembrolizumab is redefining the MIBC treatment paradigm
2
Cretostimogene Grenadenorepvec: Mechanism and Rationale
3
The Unmet Need in BCG-Unresponsive NMIBC
4
Published BOND-003 data show durable responses with cretostimogene in NMIBC
5